InspireMD's CGuard Prime 80cm Shows 100% Success in TCAR Trial, Zero Adverse Events
NSPR is trading near its 52-week low of $0.75 (15% above the low).
Summary
InspireMD announced exceptionally strong 30-day results from its CGUARDIANS II clinical trial for the CGuard Prime 80 cm implant, showing 100% acute device success and zero major adverse events in TCAR procedures. These highly positive outcomes are crucial for the company, which has recently faced a 'going concern' warning, significant cash burn, and a product recall for a different CGuard Prime delivery system. The successful trial data could enable InspireMD to tap into the large U.S. TCAR market, estimated at 35,000 procedures annually, significantly expanding its addressable market. This potential market expansion is vital for the company's future revenue growth and financial stability. Investors will now focus on the anticipated FDA approval of the PMA supplement in the second half of 2026.
At the time of this announcement, NSPR was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.3M. The 52-week trading range was $0.75 to $2.93. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.